London blitz

It also is possible that official confirmation of an investigation by British members of Parliament of the Millargate affair may have triggered a wave of selling (see BioCentury, May 20). BBG CEO Keith McCullagh and Andrew Millar, the company's former clinical research director, are due to give evidence to the Parliament's select committee on science and technology this week.

BBG shares stock staged a small recovery and closed Friday at 36.5p, down 3 percent on the week...